Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory disorders NEC

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Respiratory disorders NEC. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-014301-14 Sponsor Protocol Number: 2009-014301-14 Start Date*: 2009-07-15
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Farmacologic prevention with Varenicline in heavy smokers undergoing early detection lung cancer screening
    Medical condition: Heavy smokers with higher risk in developing lung cancer and smoke related diseases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10038716 HLGT
    9.1 10029107 HLGT
    9.1 10006334 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000896-30 Sponsor Protocol Number: Uni-Koeln-439 Start Date*: 2009-02-09
    Sponsor Name:University of Cologne
    Full Title: Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks
    Medical condition: Idiopathic Respiratory Distress Syndrome (IRDS) in preterm infants
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021735 Infant respiratory distress syndrome LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005658-20 Sponsor Protocol Number: FGCL-3019-067 Start Date*: 2016-02-23
    Sponsor Name:FibroGen, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10033979 Parenchymal lung disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-003368-21 Sponsor Protocol Number: RC 03/08 Start Date*: 2008-06-04
    Sponsor Name:ISTITUTO PER L`INFANZIA BURLO GAROFOLO
    Full Title: Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX)
    Medical condition: For patients with a stabilized clinical condition, not recovered in care units for acute problems.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003816 HLGT
    9.1 10027657 HLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016778-34 Sponsor Protocol Number: TH09001 Start Date*: 2010-01-27
    Sponsor Name:THERABEL LUCIEN PHARMA
    Full Title: Evaluation de la non-infériorité de l’efficacité d’Helicidine® versus Sirop à base de dextromethorphane sur la toux sèche des patients pris en charge en médecine générale.
    Medical condition: Patients volontaires présentant un épisode de toux sèche et venant consulter en médecine générale.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013773 Dry cough LLT
    12.1 10011224 Cough LLT
    12.1 10011233 Coughing and associated symptoms HLT
    12.1 10038716 Respiratory disorders NEC HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003666-41 Sponsor Protocol Number: MEC2020-0078 Start Date*: 2020-04-21
    Sponsor Name:Erasmus MC University Medical Center
    Full Title: Doxapram versus placebo in preterm newborns: an international double blinded multicenter randomized controlled trial.
    Medical condition: Preterm infants are at high risk of respiratory failure due to immaturity of the respiratory system. Respiratory failure is caused by a comprised lung function and impaired control of breathing. Co...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077323 Infantile mixed apnea LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001102-14 Sponsor Protocol Number: Ritazarem Start Date*: Information not available in EudraCT
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis
    Medical condition: ANCA vasculitis.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10047889 Wegeners granulomatosis LLT
    15.0 10047065 - Vascular disorders 10047888 Wegener's granulomatosis PT
    15.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002177-34 Sponsor Protocol Number: 10 150 02 Start Date*: 2013-11-07
    Sponsor Name:CHU de Toulouse
    Full Title: Population pharmacokinetics of levofloxacin in intensive care patients with severe community-acquired pneumonia
    Medical condition: community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10032502 Other specified alveolar and parietoalveolar pneumopathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002062-13 Sponsor Protocol Number: WA25615 Start Date*: 2013-01-18
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Phase IIa, International, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety and Pharmacokinetics of 4× 375 mg/m2 Intravenous Rituximab in Pediatric Patients with Severe Granul...
    Medical condition: granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10047888 Wegener's granulomatosis LLT
    19.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002701-94 Sponsor Protocol Number: FUN-PIR-2020-01 Start Date*: 2021-08-13
    Sponsor Name:Fundación para la Gestión de la Investigación Biomédica de Cádiz
    Full Title: Pirfenidone for the reduction of pulmonary inflammatory and fibrogenic activity in patients with silicosis due to artificial stone and progressive massive fibrosis.
    Medical condition: progressive massive fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10040678 Silicosis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10036805 Progressive massive fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000453-41 Sponsor Protocol Number: BMBF-Fz01KG1602 Start Date*: 2018-05-29
    Sponsor Name:University Hospital Tuebingen
    Full Title: Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety...
    Medical condition: Extremely low gestational age neonates (ELGANs), i.e. those who are born at <28 weeks gestation and who uniformly suffer from intermittent hypoxemic episodes.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    20.1 10017947 - Gastrointestinal disorders 10055667 Necrotising enterocolitis neonatal PT
    20.1 10018065 - General disorders and administration site conditions 10011912 Death neonatal PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10071101 Primary apnoea of premature newborns LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005535-24 Sponsor Protocol Number: ABROGATE-5527 Start Date*: 2016-06-07
    Sponsor Name:Univeristy of South Florida
    Full Title: Abatacept (CTLA4-Ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (Wegener's)
    Medical condition: Granulomatosis with polyangiitis (GPA; Wegener's granulomatosis)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10047889 Wegeners granulomatosis LLT
    19.0 100000004866 10047888 Wegener's granulomatosis LLT
    19.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001219-30 Sponsor Protocol Number: NO005-NK103 Start Date*: 2012-01-17
    Sponsor Name:Nordic Pharma SAS
    Full Title: Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus versus Conventional Therapy in Relapse of Granulomatosis with Polyangiitis ...
    Medical condition: Relapse of Wegener’s Granulomatosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10047888 Wegener's granulomatosis PT
    14.0 10047065 - Vascular disorders 10047889 Wegeners granulomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Temporarily Halted) GB (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002974-11 Sponsor Protocol Number: IBU24h-EchoG Start Date*: 2016-11-10
    Sponsor Name:María Carmen Bravo Laguna
    Full Title: Phase III, randomized, multicenter, double-blind clinical trial to evaluate two echo-guided administration regimens of ibuprofen in the treatment of patent ductus arteriosus: impact on intestinal p...
    Medical condition: patent ductus arteriosus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10034130 Patent ductus arteriosus PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004569-33 Sponsor Protocol Number: HGS1006-C1100 Start Date*: 2012-12-20
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission ...
    Medical condition: Wegener’s granulomatosis (WG) Microscopic polyangiitis (MPA) Vasculitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10047888 Wegener's granulomatosis LLT
    16.1 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Completed) IE (Completed) SE (Completed) HU (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001393-16 Sponsor Protocol Number: SHP607-202 Start Date*: 2019-06-21
    Sponsor Name:Premacure AB
    Full Title: A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Co...
    Medical condition: Chronic Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066204 Chronic lung disease of prematurity LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) SE (Prematurely Ended) FR (Completed) DE (Trial now transitioned) PT (Trial now transitioned) ES (Temporarily Halted) FI (Trial now transitioned) NL (Trial now transitioned) PL (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005752-10 Sponsor Protocol Number: AT-100/001 Start Date*: 2023-04-20
    Sponsor Name:Airway Therapeutics, Inc.
    Full Title: A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention with AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Br...
    Medical condition: Bronchopulmonary Dysplasia (BPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004297-26 Sponsor Protocol Number: C19-29 Start Date*: 2020-04-17
    Sponsor Name:Institut National de la Santé et de la Recherche Médicale (INSERM)
    Full Title: Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen
    Medical condition: Patent ductus arteriosus
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) EE (Completed) IE (Completed) FI (Completed) BE (Completed) PT (Completed) SE (Completed) HU (Completed) DK (Completed) GB (Not Authorised) NO (Completed) AT (Completed) GR (Completed) PL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023777-19 Sponsor Protocol Number: SToP-BPD Start Date*: Information not available in EudraCT
    Sponsor Name:Academic Medical Center
    Full Title: Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants: the SToP-BPD study
    Medical condition: bronchopulmonary dysplasia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006475 Bronchopulmonary dysplasia LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002670-39 Sponsor Protocol Number: PROXI2017 Start Date*: 2018-02-01
    Sponsor Name:Bispebjerg Hospital
    Full Title: Hyperoxia and antioxidant intervention during major non-cardiac surgery and risk of cerebral and cardiovascular complications, a blinded 2x2 factorial randomized clinical trial
    Medical condition: Patients undergoing major non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10007654 Cardiovascular injuries HLT
    20.0 10042613 - Surgical and medical procedures 10064939 Cardiovascular event prophylaxis PT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    20.0 100000004849 10032964 Other symptoms involving cardiovascular system LLT
    20.0 100000004869 10078955 Cardiovascular risk LLT
    20.0 10042613 - Surgical and medical procedures 10052616 Intraoperative care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 12:17:46 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA